Phase III trial for the ABNCoV2 COVID-19 vaccine to start inclusion of Danish subjects
Hørsholm, Denmark, October 7, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Bavarian Nordic’s ongoing Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine, which started to include subjects in the United States in September, will also start to include subjects in Denmark in October. The Danish part of the study will be conducted at hospitals on Zealand, Jutland and Funen.Danish subjects included in the study will assist in the evaluation of the ABNCoV2 vaccine